208 related articles for article (PubMed ID: 35632550)
21. SARS-CoV2 wild type and mutant specific humoral and T cell immunity is superior after vaccination than after natural infection.
Richardson JR; Götz R; Mayr V; Lohse MJ; Holthoff HP; Ungerer M
PLoS One; 2022; 17(4):e0266701. PubMed ID: 35468147
[TBL] [Abstract][Full Text] [Related]
22. Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant.
Zuo F; Abolhassani H; Du L; Piralla A; Bertoglio F; de Campos-Mata L; Wan H; Schubert M; Cassaniti I; Wang Y; Sammartino JC; Sun R; Vlachiotis S; Bergami F; Kumagai-Braesch M; Andréll J; Zhang Z; Xue Y; Wenzel EV; Calzolai L; Varani L; Rezaei N; Chavoshzadeh Z; Baldanti F; Hust M; Hammarström L; Marcotte H; Pan-Hammarström Q
Nat Commun; 2022 May; 13(1):2670. PubMed ID: 35562366
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of Long-Term Adaptive Immune Responses Specific to SARS-CoV-2: Effect of Various Vaccination and Omicron Exposure.
Kang H; Jung J; Ko GY; Lee J; Oh EJ
Vaccines (Basel); 2024 Mar; 12(3):. PubMed ID: 38543935
[TBL] [Abstract][Full Text] [Related]
24. Extensive neutralization against SARS-CoV-2 variants elicited by Omicron-specific subunit vaccine as a heterologous booster.
Peng P; Feng C; Hu J; He C; Deng H; Fan Q; Xiang J; Tang G; Jiang ML; Hu F; Li F; Wang K; Tang N; Tang XP; Huang A
iScience; 2022 Nov; 25(11):105465. PubMed ID: 36338432
[TBL] [Abstract][Full Text] [Related]
25. Heterologous vaccination with subunit protein vaccine induces a superior neutralizing capacity against BA.4/5-included SARS-CoV-2 variants than homologous vaccination of mRNA vaccine.
Peng D; Zhao T; Hong W; Fu M; He C; Chen L; Ren W; Lei H; Yang J; Alu A; Ni Y; Liu J; Li J; Wang W; Shen G; Zhao Z; Yang L; Yang J; Wang Z; Tanaka Y; Lu G; Song X; Wei X
MedComm (2020); 2023 Apr; 4(2):e238. PubMed ID: 36911160
[TBL] [Abstract][Full Text] [Related]
26. Booster BNT162b2 COVID-19 Vaccination Increases Neutralizing Antibody Titers Against the SARS-CoV-2 Omicron Variant in Both Young and Elderly Adults.
Um J; Choi YY; Kim G; Kim MK; Lee KS; Sung HK; Kim BC; Lee YK; Jang HC; Bang JH; Chung KH; Oh MD; Park JS; Jeon J
J Korean Med Sci; 2022 Mar; 37(9):e70. PubMed ID: 35257525
[TBL] [Abstract][Full Text] [Related]
27. A nasal omicron vaccine booster elicits potent neutralizing antibody response against emerging SARS-CoV-2 variants.
Lam JY; Ng YY; Yuen CK; Wong WM; Yuen KY; Kok KH
Emerg Microbes Infect; 2022 Dec; 11(1):964-967. PubMed ID: 35275039
[TBL] [Abstract][Full Text] [Related]
28. Correlation Analysis of Anti-SARS-CoV-2 RBD IgG and Neutralizing Antibody against SARS-CoV-2 Omicron Variants after Vaccination.
Takheaw N; Liwsrisakun C; Chaiwong W; Laopajon W; Pata S; Inchai J; Duangjit P; Pothirat C; Bumroongkit C; Deesomchok A; Theerakittikul T; Limsukon A; Tajarernmuang P; Niyatiwatchanchai N; Trongtrakul K; Kasinrerk W
Diagnostics (Basel); 2022 May; 12(6):. PubMed ID: 35741126
[TBL] [Abstract][Full Text] [Related]
29. Immunogenicity of BNT162b2 Vaccination against SARS-CoV-2 Omicron Variant and Attitudes toward a COVID-19 Booster Dose among Healthy Thai Adolescents.
Assavavongwaikit P; Chantasrisawad N; Himananto O; Phasomsap C; Klawaja P; Cartledge S; Nadsasarn R; Jupimai T; Kawichai S; Anugulruengkitt S; Puthanakit T; On Behalf Of The Study Team
Vaccines (Basel); 2022 Jul; 10(7):. PubMed ID: 35891264
[TBL] [Abstract][Full Text] [Related]
30. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
[TBL] [Abstract][Full Text] [Related]
31. Sequentially immune-induced antibodies could cross-neutralize SARS-CoV-2 variants.
Lv Q; Zhou S; Qi F; Zhang Y; Li F; Liu M; Bao L
Animal Model Exp Med; 2022 Feb; 5(1):89-93. PubMed ID: 35213787
[TBL] [Abstract][Full Text] [Related]
32. Differential avidity determination of IgG directed towards the receptor-binding domain (RBD) of SARS-CoV-2 wild-type and its variants in one assay: Rational tool for the assessment of protective immunity.
Bauer G; Struck F; Staschik E; Maile J; Wochinz-Richter K; Motz M; Soutschek E
J Med Virol; 2022 Nov; 94(11):5294-5303. PubMed ID: 35851961
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of humoral and cellular response to four vaccines against COVID-19 in different age groups: A longitudinal study.
Fedele G; Trentini F; Schiavoni I; Abrignani S; Antonelli G; Baldo V; Baldovin T; Bandera A; Bonura F; Clerici P; De Paschale M; Fortunato F; Gori A; Grifantini R; Icardi G; Lazzarotto T; Lodi V; Mastroianni CM; Orsi A; Prato R; Restivo V; Carsetti R; Piano Mortari E; Leone P; Olivetta E; Fiore S; Di Martino A; Brusaferro S; Merler S; Palamara AT; Stefanelli P
Front Immunol; 2022; 13():1021396. PubMed ID: 36389704
[TBL] [Abstract][Full Text] [Related]
34. The impact of CoronaVac on the neutralization breadth and magnitude of the antibody response to SARS-CoV-2 viruses.
Zhang L; Chen H; Yang S; Zhao Y; Shen X; He X; Ye H; Wang D; Lou J; Wang Y; Wu S
Front Immunol; 2022; 13():990071. PubMed ID: 36203574
[TBL] [Abstract][Full Text] [Related]
35. Characterization of the Antibody and Interferon-Gamma Release Response after a Second COVID-19 Booster Vaccination.
Grikscheit K; Rabenau HF; Ghodratian Z; Widera M; Wilhelm A; Toptan Grabmair T; Hoehl S; Layer E; Helfritz F; Ciesek S
Vaccines (Basel); 2022 Jul; 10(7):. PubMed ID: 35891326
[TBL] [Abstract][Full Text] [Related]
36. Immunogenicity of BNT162b2 vaccine booster against SARS-CoV-2 Delta and Omicron variants in nursing home residents: A prospective observational study in older adults aged from 68 to 98 years.
Alidjinou EK; Demaret J; Corroyer-Simovic B; Labreuche J; Goffard A; Trauet J; Lupau D; Miczek S; Vuotto F; Dendooven A; Huvent-Grelle D; Podvin J; Dreuil D; Faure K; Deplanque D; Bocket L; Duhamel A; Sobaszek A; Hober D; Hisbergues M; Puisieux F; Autran B; Yazdanpanah Y; Labalette M; Lefèvre G
Lancet Reg Health Eur; 2022 Jun; 17():100385. PubMed ID: 35469147
[TBL] [Abstract][Full Text] [Related]
37. Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults - VISION Network, 10 States, December 2021-March 2022.
Natarajan K; Prasad N; Dascomb K; Irving SA; Yang DH; Gaglani M; Klein NP; DeSilva MB; Ong TC; Grannis SJ; Stenehjem E; Link-Gelles R; Rowley EA; Naleway AL; Han J; Raiyani C; Benitez GV; Rao S; Lewis N; Fadel WF; Grisel N; Griggs EP; Dunne MM; Stockwell MS; Mamawala M; McEvoy C; Barron MA; Goddard K; Valvi NR; Arndorfer J; Patel P; Mitchell PK; Smith M; Kharbanda AB; Fireman B; Embi PJ; Dickerson M; Davis JM; Zerbo O; Dalton AF; Wondimu MH; Azziz-Baumgartner E; Bozio CH; Reynolds S; Ferdinands J; Williams J; Schrag SJ; Verani JR; Ball S; Thompson MG; Dixon BE
MMWR Morb Mortal Wkly Rep; 2022 Apr; 71(13):495-502. PubMed ID: 35358170
[TBL] [Abstract][Full Text] [Related]
38. A booster dose of Delta × Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants.
Lee IJ; Sun CP; Wu PY; Lan YH; Wang IH; Liu WC; Yuan JP; Chang YW; Tseng SC; Tsung SI; Chou YC; Kumari M; Lin YS; Chen HF; Chen TY; Lin CC; Chiu CW; Hsieh CH; Chuang CY; Cheng CM; Lin HT; Chen WY; Hsu FF; Hong MH; Liao CC; Chang CS; Liang JJ; Ma HH; Chiang MT; Liao HN; Ko HY; Chen LY; Ko YA; Yu PY; Yang TJ; Chiang PC; Hsu ST; Lin YL; Lee CC; Wu HC; Tao MH
J Biomed Sci; 2022 Jul; 29(1):49. PubMed ID: 35799178
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness of a COVID-19 Additional Primary or Booster Vaccine Dose in Preventing SARS-CoV-2 Infection Among Nursing Home Residents During Widespread Circulation of the Omicron Variant - United States, February 14-March 27, 2022.
Prasad N; Derado G; Nanduri SA; Reses HE; Dubendris H; Wong E; Soe MM; Li Q; Dollard P; Bagchi S; Edwards J; Shang N; Budnitz D; Bell J; Verani JR; Benin A; Link-Gelles R; Jernigan J; Pilishvili T
MMWR Morb Mortal Wkly Rep; 2022 May; 71(18):633-637. PubMed ID: 35511708
[TBL] [Abstract][Full Text] [Related]
40. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
